Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

<< Previous

Bullboard Posts

Next >>

Post by waves1on Oct 13, 2022 5:32pm

108 Views

Post# 35023529

AGN Update Webinar: IPF & DMT trials, ODD & more

Replay link to watch AGN's most recent webinar with Radius Research: https://www.youtube.com/watch?v=KXzh3-86szc&ab_channel=RadiusResearch

AGN CEO Chris Moreau provides a business update and covers the two upcoming trials, Phase IIb of Ifenprodil and Phase I of DMT, as well as their filing for orphan drug designation.

The timeline going forward has Phase I of DMT beginning in Q4 2022, IPF getting ODD between Q4 2022 and Q1 2023 and Phase I CKD Study beginning in Q1 2023 with the study data expected later in the year.

<< Previous

Bullboard Posts

Next >>

Looking at: Is Taylor Swift the key to solving traffic in Toronto?